About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Post-GSK: Where Do We Go from Here? - Increased Fees for Continuations | Main | Ocean Tomo® Announces Results of IP Auction Held on October 25, 2007 »

November 09, 2007

Comments

Congratulations to the best bio-patent blog. Keep up the great work! Special kudos to Kevin Noonan for his sensible, thoughtful insights.

One suggestion (which I think is already beginning to be taken up here): I'd like to see a more international perspective. The USA tends to be rather insular which is not surprising given its premier market value. However, as is abundantly clear these days, its patent system is hardly free from flaws, possibly arising from its unique features. For example, I am not aware of continuations being available anywhere outside the US other than divisionals, and usually those are intended for distinct inventions under the PCT-style unity concept. (On the other hand, may be divisionals are used in practice as a type of continuation in other jurisdictions? In Canada, that would not be feasible because of double patenting, but may be in Australia?).

Perhaps you could have a guest blogger to offer a non-US perspective?

Thanks for running this blog. It provides a real service to the profession. I have signed on only recently, and find the information and insight helpful even though I am not a biotech practitioner and do not handle much pharma work either.

The comments to this entry are closed.

May 2024

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31